Infosys Partners With Economist Group To Advance Sustainability Solutions

Infosys Limited (INFY) announced Wednesday a new strategic partnership with media company The Economist Group to enable and accelerate sustainability solutions.

Infosys, as Digital Innovation Partner, will power Economist Group's latest global initiative to advance the discourse on sustainability amongst world leaders and businesses.

The companies plan to drive world-changing impact through a new business-to-business model. The initiative is designed to unlock the long-term thinking of businesses and other institutions.

The first phase of the strategic, multi-year partnership will be announced and launched in October 2021. Infosys' groundbreaking digital services and capabilities will be combined with the strength and depth of Economist Group's policy research, insights and events expertise.

Lara Boro, CEO, Economist Group, said, "This exciting partnership with Infosys shows how pooling strengths can accelerate innovation and amplify impact in the pursuit of progress."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT